TargetMol

Rotigotine Hydrochloride

Product Code:
 
TAR-T21446
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21446-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21446-1mL1 mL * 10 mM (in DMSO)£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21446-10mg10mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21446-25mg25mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21446-50mg50mg£183.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21446-100mg100mg£228.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rotigotine Hydrochloride, a dopamine receptor agonist prefering for D3 receptors over D1 and D2, has effective activity of anti-Parkinsonian. Racemic rotigotine hydrochloride is about 50 times as potent as quinpirole, the gold standard D2 agonist.
CAS:
125572-93-2
Formula:
C19H26ClNOS
Molecular Weight:
351.93
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9966
SMILES:
Cl.CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor

References

1. Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. J Parkinsons Dis. 2016 Apr 2. [Epub ahead of print] PubMed PMID: 27061066. 2. Cannas A, Meloni M, Mascia MM,et al. Priapism and Hypersexuality Associated With Rotigotine in an Elderly Parkinsonian Patient: A Case Report. Clin Neuropharmacol. 2016 Apr 4. [Epub ahead of print] PubMed PMID: 27046660. 3. LeWitt PA, Poewe W, Elmer LW, et al. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. 4. Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, Goldammer N, Schollmayer E, Schr?der H, Winkelman JW. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. Am J Kidney Dis. 2016 Feb 2. pii: S0272-6386(16)00018-4.